WHV’s HIV vaccine candidate PDPHV-201401 is based on extensive preclinical and clinical research conducted in Dr. Shan Lu’s laboratory at the University of Massachusetts Medical School. It takes advantage of three main principles, which have been shown to generate robust and broad anti-HIV responses : polyvalency of immunogens, DNA priming followed by protein boosting, and matching prime/boost immunogens. Learn more about the Vaccine Approach.
This polyvalent matching DNA-prime/protein-boost approach has been shown to be highly immunogenic in small animal models, and in non-human primates. The elicited immune responses include broadly-reactive functional antibodies and strong T cell responses. This strategy provides sterilizing protection in vaccinated non-human primates. The responses persist for at least two years after the last vaccine dose. Learn more about our Preclinical Studies.
The first generation of this vaccine concept was tested in a Phase I clinical trial DP6-001. The second generation of the vaccine candidate was recently testing in a Phase Ia trial HVTN124 and is currently being tested in a Phase Ib clinical trial WHV138. Learn more about Our Clinical Trials.
